Jade Biosciences, Inc. JBIO R2K
Healthcare · Biotechnology · United States
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
READ MORE ›$21.04
+190.21% 1Y
Market & Price
Market Cap
$1.04B
Current Price
$21.04
High / Low (52W)
$26.85 / $6.76
Beta
-
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.01
Price to Book
3.50
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
-34.07%
ROE
-
ROA
-
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.57
EPS (TTM)
$-2.63
Balance Sheet & Liquidity
Debt/Equity
0.29
Quick Ratio
13.96
Current Ratio
14.29
Debt
$849.00K
Total Assets
$349.78M
Current Assets
$348.82M
Working Capital
$332.28M
Ownership
Promoter Holding
1.12%
Chg in Prom Hold
-
FII / Inst Holding
101.31%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$728.09M
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
-
Operating Cash Flow
$-100.01M
Shares Outstanding
49.36M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JBIO Jade Biosciences, Inc. R2K | 21.04 | - | $1.04B | - | -34.07% | - | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.38M | 27.78M | 27.40M | 34.98M | 43.45M |
| Operating Income | - | -1.62M | -2.24M | -2.78M | -5.77M | -6.20M | -11.02M | -12.21M | -14.15M | -17.64M | -20.34M | -21.37M | -24.62M | -26.16M | - | -23.38M | -27.78M | -27.40M | -34.98M | -43.45M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.38M | -27.77M | -27.39M | -34.97M | -43.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38.17M | -32.13M | -25.18M | -31.87M | -40.35M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 16.00K |
| Net Income | -1.44M | -2.20M | -2.31M | -2.78M | -5.78M | -6.18M | -10.91M | -11.99M | -13.59M | -16.52M | -19.02M | -19.56M | -23.19M | -24.77M | - | -38.17M | -32.13M | -25.18M | -31.93M | -40.37M |
| Diluted EPS | - | - | - | - | - | -0.26 | -0.45 | -0.49 | -0.56 | -0.67 | -0.76 | -0.71 | -0.83 | -0.86 | -0.50 | -1.18 | -0.86 | -0.48 | - | -0.57 |
| R&D Expense | - | 1.47M | 1.97M | 2.20M | 4.33M | 3.42M | 7.25M | 8.36M | 10.78M | 13.49M | 16.03M | 16.88M | 20.08M | 21.25M | 13.66M | 20.02M | 22.55M | 22.01M | - | 36.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 113.54M |
| Operating Income | -8.89M | -23.02M | -53.24M | -81.41M | -74.60M | -113.54M |
| EBITDA | - | - | - | - | - | -113.52M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -127.35M |
| Tax Provision | - | - | - | - | - | 58.00K |
| Net Income | -9.61M | -22.96M | -51.51M | -75.52M | -69.63M | -127.41M |
| Diluted EPS | - | -1.87 | -2.10 | -2.87 | -2.44 | -3.19 |
| R&D Expense | 7.94M | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.71M | 175.36M | 135.30M | 127.42M | - | 72.80M | 349.78M |
| Current Assets | - | - | - | - | - | - | 69.65M | 348.82M |
| Cash & Equivalents | - | 4.57M | 54.20M | 22.40M | 23.49M | - | 69.39M | 88.44M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 1.77M | 2.94M | 8.56M | 17.96M | - | 119.60M | 17.26M |
| Current Liabilities | - | 1.77M | 2.55M | 7.78M | 17.64M | - | 12.00M | 16.54M |
| Long Term Debt | - | - | - | - | - | - | 107.60M | - |
| Total Debt | - | - | - | - | - | - | 107.60M | 724.00K |
| Total Equity | -3.64M | -13.34M | 172.42M | 126.74M | 109.46M | 1.00K | -46.80M | 332.52M |
| Shares Outstanding | - | - | - | - | - | - | 32.24M | 49.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.86M | -27.40M | -39.12M | -56.78M | -71.20M | -94.69M |
| Investing Cash Flow | - | -113.43M | 6.93M | 11.88M | 56.03M | -247.01M |
| Financing Cash Flow | 8.92M | 190.46M | 396.00K | 46.00M | 25.43M | 360.77M |
| Capital Expenditure | - | -181.00K | -195.00K | -142.00K | - | -196.00K |
| Free Cash Flow | - | -27.58M | -39.32M | -56.92M | - | -94.89M |
| Net Change in Cash | - | - | - | - | - | 19.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 72.0% | -13.3% | -40.6% | -69.0% | 148.8% | -38.3% |
| ROCE % | -302.2% | -13.3% | -41.7% | -74.2% | -122.7% | -34.1% |
Shareholding Pattern
Insiders
1.12%
Institutions
101.31%
Public Float
102.45%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.35% | 7.09M | $149.08M |
| 2 | Fairmount Funds Management LLC | 9.23% | 4.55M | $95.81M |
| 3 | RA Capital Management, L.P. | 7.44% | 3.67M | $77.24M |
| 4 | Bellevue Group AG | 7.09% | 3.50M | $73.67M |
| 5 | Venrock Adviser, LLC | 6.52% | 3.22M | $67.76M |
| 6 | Janus Henderson Group PLC | 6.29% | 3.11M | $65.34M |
| 7 | Blackrock Inc. | 4.69% | 2.31M | $48.69M |
| 8 | Vanguard Capital Management LLC | 3.64% | 1.80M | $37.80M |
| 9 | Baker Bros. Advisors, LP | 3.32% | 1.64M | $34.53M |
| 10 | Remedium Capital Partners, LLC | 3.20% | 1.58M | $33.20M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JBIO
No recent headlines available.